Firefly Neuroscience, Inc. AIFF
2.01
0.82
68.91%
as of 25 Sep
- Market cap
- $18.7M
- P/E
- 0.0×
Follow AIFF
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (70.52%) | (136.27%) | (675.60%) | (411.76%) |
+8 more TTM periods Free account |
|
| (59.52%) | (79.79%) | (325.39%) | (288.94%) | ||
ROIC |
(105.08%) | (103.49%) | (113.19%) | (114.77%) | |
Return on Tangible Assets |
(112.91%) | (421.28%) | (1,811.74%) | (868.87%) | |
Average Days of Receivables |
38.14 | 44.47 | 62.01 | 85.77 | |
Free Cash Flow per Share |
(0.35) | (0.48) | (0.67) | (0.59) | |
Free Cash Flow |
(7.20) | (7.81) | (8.32) | (7.93) | |
Capital Expenditures |
(0.21) | (0.18) | (0.13) | (0.32) | |
Piotroski F-Score |
4.00 | 4.00 | 3.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(29.26%) | (65.96%) | (78.91%) | (54.41%) | |
Accounts Receivable Turnover |
12.49 | 10.09 | 8.16 | 1.61 | |
Accounts Payable Turnover |
0.84 | 0.52 | 1.09 | 1.98 | |
Inventory Turnover |
11.27 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
322.53 | 637.43 | 286.20 | 181.56 | |
Days of Inventory on Hand |
16.11 | 49.40 | 22.95 | 10.80 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
99.11% | 100.63% | 129.77% | 186.85% | |
Selling, General and Administrative Expense of Revenue |
439.63% | 491.10% | 680.21% | 998.47% | |
Share Based Compensation of Revenue |
89.22% | 100.25% | 118.21% | 94.51% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 0.82 | 0.33 | 0.30 | |
Depreciation/Fixed assets |
1.97 | 2.28 | 2.90 | 5.13 | |
Capex/Depreciation |
(0.46) | (0.40) | (0.30) | (0.27) | |
Revenue per Share |
0.09 | 0.10 | 0.09 | 0.06 | |
Operating CF per Share |
(0.34) | (0.47) | (0.66) | (0.56) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.02) | |
Capex to Sales |
0.12 | 0.11 | 0.11 | 0.41 | |
Net Profit Margin |
(524.51%) | (586.17%) | (2,148.07%) | (3,269.09%) |
Columns are period end dates